647 related articles for article (PubMed ID: 29138992)
21. The use of ketamine in electroconvulsive therapy.
Kucia K; Merk W
Psychiatr Pol; 2015; 49(6):1255-63. PubMed ID: 26909400
[TBL] [Abstract][Full Text] [Related]
22. Ketamine for depression.
Jelen LA; Stone JM
Int Rev Psychiatry; 2021 May; 33(3):207-228. PubMed ID: 33569971
[TBL] [Abstract][Full Text] [Related]
23. Comparative study of low-dose ketamine infusion and repetitive transcranial magnetic stimulation in treatment-resistant depression: A posthoc pooled analysis of two randomized, double-blind, placebo-controlled studies.
Chen MH; Cheng CM; Li CT; Tsai SJ; Lin WC; Bai YM; Su TP
Psychiatry Res; 2022 Oct; 316():114749. PubMed ID: 35940087
[TBL] [Abstract][Full Text] [Related]
24. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Murrough JW; Perez AM; Pillemer S; Stern J; Parides MK; aan het Rot M; Collins KA; Mathew SJ; Charney DS; Iosifescu DV
Biol Psychiatry; 2013 Aug; 74(4):250-6. PubMed ID: 22840761
[TBL] [Abstract][Full Text] [Related]
25. Augmentation Therapy With Serial Intravenous Ketamine Over 18 Months in a Patient With Treatment Resistant Depression.
Hassamal S; Spivey M; Pandurangi AK
Clin Neuropharmacol; 2015; 38(5):212-6. PubMed ID: 26366968
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression.
Bottemanne H; Morlaas O; Claret A; Sharot T; Fossati P; Schmidt L
JAMA Psychiatry; 2022 Nov; 79(11):1124-1132. PubMed ID: 36169969
[TBL] [Abstract][Full Text] [Related]
27. Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective.
López-Díaz Á; Murillo-Izquierdo M; Moreno-Mellado E
Br J Psychiatry; 2019 Aug; 215(2):447-448. PubMed ID: 31030677
[TBL] [Abstract][Full Text] [Related]
28. The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review.
Di Vincenzo JD; Siegel A; Lipsitz O; Ho R; Teopiz KM; Ng J; Lui LMW; Lin K; Cao B; Rodrigues NB; Gill H; McIntyre RS; Rosenblat JD
J Psychiatr Res; 2021 May; 137():232-241. PubMed ID: 33706168
[TBL] [Abstract][Full Text] [Related]
29. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
Singh JB; Fedgchin M; Daly EJ; Drevets WC
Adv Pharmacol; 2020; 89():237-259. PubMed ID: 32616208
[TBL] [Abstract][Full Text] [Related]
30. The immunomodulatory effect of ketamine in depression.
Szałach ŁP; Lisowska KA; Słupski J; Włodarczyk A; Górska N; Szarmach J; Jakuszkowiak-Wojten K; Gałuszko-Węgielnik M; Wiglusz MS; Wilkowska A; Cubała WJ
Psychiatr Danub; 2019 Sep; 31(Suppl 3):252-257. PubMed ID: 31488736
[TBL] [Abstract][Full Text] [Related]
31. [Ketamine's antidepressant effect: literature review on clinical use].
De Maricourt P; Jay T; Goncalvès P; Lôo H; Gaillard R
Encephale; 2014 Feb; 40(1):15-23. PubMed ID: 24434008
[TBL] [Abstract][Full Text] [Related]
32. [Antidepressant effect of ketamine, a N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, in the therapy of treatment-resistant depression].
Gosek P; Chojnacka M; Bieńkowski P; Swiecicki Ł
Psychiatr Pol; 2012; 46(2):283-94. PubMed ID: 23214398
[TBL] [Abstract][Full Text] [Related]
33. Oral S-ketamine effective after deep brain stimulation in severe treatment-resistant depression and extensive comorbidities.
Veraart JKE; Kamphuis J; Schlegel M; Schoevers RA
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33495180
[TBL] [Abstract][Full Text] [Related]
34. The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research.
Gill H; Gill B; Rodrigues NB; Lipsitz O; Rosenblat JD; El-Halabi S; Nasri F; Mansur RB; Lee Y; McIntyre RS
Neurosci Biobehav Rev; 2021 Jan; 120():78-85. PubMed ID: 33242561
[TBL] [Abstract][Full Text] [Related]
35. Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review.
Caldiroli A; Capuzzi E; Tagliabue I; Capellazzi M; Marcatili M; Mucci F; Colmegna F; Clerici M; Buoli M; Dakanalis A
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884874
[TBL] [Abstract][Full Text] [Related]
36. Intravenous ketamine for treatment-resistant depression patients who have failed to respond to transcranial magnetic stimulation: A case series.
Payette O; Lespérance P; Desbeaumes Jodoin V; Longpré-Poirier C; Elkrief L; Richard M; Garel N; Miron JP
J Affect Disord; 2023 Jul; 333():18-20. PubMed ID: 37075822
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
Ochs-Ross R; Daly EJ; Zhang Y; Lane R; Lim P; Morrison RL; Hough D; Manji H; Drevets WC; Sanacora G; Steffens DC; Adler C; McShane R; Gaillard R; Wilkinson ST; Singh JB
Am J Geriatr Psychiatry; 2020 Feb; 28(2):121-141. PubMed ID: 31734084
[TBL] [Abstract][Full Text] [Related]
38. Ketamine for Treatment-Resistant Depression: a New Advocate.
Pérez-Esparza R
Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
[TBL] [Abstract][Full Text] [Related]
39. Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression.
Olgiati P; Serretti A; Souery D; Dold M; Kasper S; Montgomery S; Zohar J; Mendlewicz J
J Affect Disord; 2018 Feb; 227():777-786. PubMed ID: 29254066
[TBL] [Abstract][Full Text] [Related]
40. New medications for treatment-resistant depression: a brief review of recent developments.
Thase ME
CNS Spectr; 2017 Dec; 22(S1):39-48. PubMed ID: 29350129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
